Home > Insider Trading > Filing (0001209191-22-004795)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1396814	Pacira Biosciences Inc.	PCRX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1296965	Marie Kristen Williams	C/O Pacira Biosciences, Inc. 5401 West Kennedy Boulevard, Suite 890 Tampa FL 33609	Chief Administrative Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-01-21	200	$38.35	22,468	No	4	M	Direct
Common Stock	Disposition	2022-01-21	200	$65.41	22,268	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2022-01-21	200	$0.00	200	$38.35

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
9,766		2028-06-13	No	4	M	Direct

Footnotes

The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.365 to $65.460, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.